Evidence map›Paper›PMID 37338678›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2023

CaMKK2 alleviates myocardial ischemia/reperfusion injury by inhibiting oxidative stress and inflammation via the action on the AMPK-AKT-GSK-3β/Nrf2 signaling cascade.

Chengliang Li, Jiajia Hao, Huichang Qiu, Hong Xin

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Chengliang Li *Department of General Practice, Guangzhou First People's Hospital, Guangzhou, 510180, China.
Jiajia Hao *Department of General Practice, Guangzhou First People's Hospital, Guangzhou, 510180, China.
Huichang QiuDepartment of General Practice, Guangzhou First People's Hospital, Guangzhou, 510180, China.
Hong XinHealthcare Simulation Center, Department of Research, Education and Information, Guangzhou First People's Hospital, No.1 Panfu Road, Guangzhou, 510180, China. xinhongxh77@163.com.
Guangzhou First People's Hospital · CNGuangzhou Medical University · CN

Funding

General Teaching Reform Project of South China University of Technology 2022-10Guangzhou First People's Hospital Red Cotton Plan Project 2023-06Shaanxi Natural Science Foundation Project 2022SF-132
6 · The paper itself

Abstract

objectiveCalcium/calmodulin-dependent protein kinase kinase 2 (CaMKK2) can regulate numerous biological processes and is implicated in diverse pathological processes. Yet its role in myocardial ischemia/reperfusion (MI/R) injury remains unknown. This project explored the possible functions and mechanisms of CaMKK2 in MI/R injury.

methodsA rat model of MI/R in vivo was established using the left anterior descending coronary artery ligation method. Rat cardiomyocytes were exposed to hypoxia/reoxygenation (H/R) in vitro to establish a cell model. Overexpression of CaMKK2 was achieved by infecting recombinant adeno-associated virus or adenovirus expressing CaMKK2. Real-time quantitative PCR, immunoblotting, TTC staining, TUNEL assay, ELISA, oxidative stress detection assays, flow cytometry, and CCK-8 assay were carried out.

resultsA decline in CaMKK2 levels was induced by MI/R in vivo or H/R in vitro. Up-modulation of CaMKK2 in rats ameliorated the cardiac injury evoked by MI/R injury accompanied by suppression of cardiac apoptosis, oxidative stress, and proinflammatory response. Rat cardiomyocytes with CaMKK2 overexpression were also protected from H/R damage by inhibiting apoptosis, oxidative stress, and proinflammatory response. CaMKK2 overexpression led to increased phosphorylation of AMPK, AKT, and GSK-3β, and enhanced activation of Nrf2 under MI/R or H/R conditions. Inhibition of AMPK abolished CaMKK2-mediated Nrf2 activation and relevant cardioprotective effect. Restraint of Nrf2 also diminished CaMKK2-mediated relevant cardioprotective effect.

conclusionsUp-regulation of CaMKK2 provides a therapeutic benefit in the rat model of MI/R injury by boosting the Nrf2 pathway through regulation of AMPK/AKT/GSK-3β, which suggests CaMKK2 as a new molecular target for the treatment of MI/R injury.

Indexed as

Myocardial Reperfusion InjuryProto-Oncogene Proteins c-aktAMP-Activated Protein KinasesAnimalsApoptosisGlycogen Synthase Kinase 3 betaInflammationMyocytes, CardiacNF-E2-Related Factor 2Oxidative StressRatsAMP-Activated Protein KinasesGlycogen Synthase Kinase 3 betaNF-E2-Related Factor 2Proto-Oncogene Proteins c-aktCaMKK2InflammationMyocardial ischemia/reperfusionNrf2Oxidative stress

Identifiers

PMID37338678
OpenAlexW4381309557

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.